MedTrace Logo

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

NCT00364091 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2011-09-27

No results posted yet for this study

Summary

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

R89674 0.025% ophthalmic solution

Sponsors & Collaborators

  • Vistakon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Reza Haque, MD · Vistakon Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00364091 on ClinicalTrials.gov